Providio MediSolutions LLC has been appointed to administer the $650 million settlement fund Boehringer Ingelheim GmbH agreed to over its blood-thinner Pradaxa.
U.S. Chief District Judge David R. Herndon ordered $561 million of the settlement funds be segregated for the first phase of payments, and $50 million be segregated as the second phase supplemental payments.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
